ClinicalTrials.gov
ClinicalTrials.gov Menu

Intervention to Reduce Injection Drug Use

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00786630
Recruitment Status : Completed
First Posted : November 6, 2008
Last Update Posted : December 23, 2014
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This is a five-year prospective randomized trial comparing two intervention conditions designed to facilitate substance abuse treatment entry and enhance retention in order to reduce the behaviors associated with HIV and HCV risk among injection drug users (IDUs) and to improve client overall functioning. The overall goal of this project is to compare strengths-based case-management (CM) to an enhanced version of CM that uses case managers to facilitate a therapeutic alliance (CM/FTA) among out-of-treatment IDUs in Denver.

Condition or disease Intervention/treatment Phase
Substance Abuse Behavioral: Strengths-based case management Behavioral: Case management plus facilitated treatment alliance Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 726 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intervention to Reduce Injection Drug Use
Study Start Date : November 2007
Actual Primary Completion Date : December 2012
Actual Study Completion Date : February 2013

Arm Intervention/treatment
Experimental: Case Management Behavioral: Strengths-based case management
Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
Experimental: Facilitated Treatment Alliance Behavioral: Case management plus facilitated treatment alliance
Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.



Primary Outcome Measures :
  1. Treatment entry and retention [ Time Frame: Baseline, 6 months after baseline, 12 months after baseline ]

Secondary Outcome Measures :
  1. Drug injection and HIV/HCV risk behaviors [ Time Frame: Baseline, 6 months after baseline, 12 months after baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • opiate injection at least 3 times a week during the last 6-months
  • 18 years of age or older
  • no drug abuse treatment in the 30-days prior to the interview
  • not transient
  • no known reason (e.g. pending jail time) why they will not be available for follow-up interviews
  • not involved in Project Safe research activities in the previous 12 months
  • willing to meet with an Addiction Research and Treatment Services (methadone clinic) counselor
  • eligible to be treated at ARTS

Exclusion Criteria:

  • too intoxicated or impaired mentally to voluntarily consent to participate in the project and/or respond to the interview

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00786630


Locations
United States, Colorado
Project Safe
Denver, Colorado, United States, 80205
Sponsors and Collaborators
University of Colorado, Denver
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Robert E. Booth, Ph.D. University of Colorado, Denver

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00786630     History of Changes
Other Study ID Numbers: 06-1131
2R01DA009832-11 ( U.S. NIH Grant/Contract )
First Posted: November 6, 2008    Key Record Dates
Last Update Posted: December 23, 2014
Last Verified: December 2014

Keywords provided by University of Colorado, Denver:
Drug treatment entry and retention
Drug injection frequency
HIV risk behaviors
Hepatitis C risk behaviors

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders